Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose

Vaccine

Volumn 30, Issue 19, 2012, Pages 3026-3033

  Smith, Jennifer Humberd ^a   Papania, Mark ^c   Knaus, Darin ^d   Brooks, Paula ^a   Haas, Debra L ^a   Mair, Raydel ^b   Barry, James ^d   Tompkins, S Mark ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d CREARE INC   (United States)

Author keywords

Aerosol; Dose sparing; Ferret; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FERRET; HISTOPATHOLOGY; INFLUENZA; INFLUENZA VACCINATION; LUNG; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FERRETS; INFLUENZA VACCINES; MALE; NEBULIZERS AND VAPORIZERS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84862806614     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.092     Document Type: Article

References (41)

1. Al Hajjar S., McIntosh K. The first influenza pandemic of the 21st century. Ann Saudi Med 2010, 30(January-February (1)):1-10.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
3. United States Census; 2010. Available from: http://2010.census.gov/2010census.
4. Seasonal influenza vaccine-total doses distributed 2010, Available from: www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm.
5. Partridge J., Kieny M.P. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010, 28(July (30)):4709-4712.
6. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(May (16)):1776-1779.
7. Huber V.C., McCullers J.A. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 2006, 193(March (5)):677-684.
8. Bush L. What we learned from H1N1. Part 1: MedImmune. BioPharm Bulletin; June 14, 2010.
9. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(November (22)):2295-2301.
10. Carter N.J., Plosker G.L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008, 22(5):279-292.
11. Treanor J., Keitel W., Belshe R., Campbell J., Schiff G., Zangwill K., et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002, 20(January (7-8)):1099-1105.
12. Koutsonanos D.G., del Pilar Martin M., Zarnitsyn V.G., Sullivan S.P., Compans R.W., Prausnitz M.R., et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 2009, 4(3):e4773.
13. Brown L.E. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 2010, 28(November (50)):8043-8045.
14. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(January (1)):1-15.
15. Suman J.D., Laube B.L., Dalby R. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm Res 1999, 16(October (10)):1648-1652.
16. Sullivan V, Bhuta-Wills A, Hajiloo S. AccuSpray™ on demand. Fluent News 2003 [cited; Spring 2003]. Available from: http://www.scribd.com/doc/26129431/HVAC-Handbook-CFD-for-HVAC-by-Fluent.
17. Low N., Kraemer S., Schneider M., Restrepo A.M. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008, 26(January (3)):383-398.
18. Chanock R.M., Murphy B.R., Collins P.L., Coelingh K.V., Olmsted R.A., Snyder M.H., et al. Live viral vaccines for respiratory and enteric tract diseases. Vaccine 1988, 6(April (2)):129-133.
19. Gruber W.C., Hinson H.P., Holland K.L., Thompson J.M., Reed G.W., Wright P.F. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993, 168(November (5)):1282-1285.
20. Rubin B.K. Air and soul: the science and application of aerosol therapy. Respir Care 2010, 55(July (7)):911-921.
21. Maher J.A., DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim (NY) 2004, 33(October (9)):50-53.
22. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 2007, 171(October (4)):1215-1223.
23. Plopper C.G., Hill L.H., Mariassy A.T. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res 1980, 1(June (2)):171-180.
24. Reed L.J., Meunch H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
25. Govorkova E.A., Kaverin N.V., Gubareva L.V., Meignier B., Webster R.G. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 1995, 172(July (1)):250-253.
26. Webster R.G., Laver W.G., Kilbourne E.D. Reactions of antibodies with surface antigens of influenza virus. J Gen Virol 1968, 3(December (3)):315-326.
27. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70(December (4)):767-777.
28. Murphy B.R., Clements M.L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989, 146:107-116.
29. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13(August (11)):1006-1012.
30. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24(July (1)):157-160.
31. Belshe R., Lee M.S., Walker R.E., Stoddard J., Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3(December (6)):643-654.
32. Zangwill K.M., Belshe R.B. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004, 23(March (3)):189-197.
33. Lu X., Edwards L.E., Desheva J.A., Nguyen D.C., Rekstin A., Stephenson I., et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006, 24(November (44-46)):6588-6593.
34. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58(May (19)):521-524.
35. Lee M.S., Mahmood K., Adhikary L., August M.J., Cordova J., Cho I., et al. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004, 23(September (9)):852-856.
36. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58(August (4)):195-207.
37. Cohen J., Enserink M. After delays, WHO agrees: the 2009 pandemic has begun. Science. Swine Flu 2009, 324(June (5934)):1496-1497.
38. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(August (RR-8)):1-62.
39. Pascua P.N., Song M.S., Lee J.H., Park K.J., Kwon H.I., Baek Y.H., et al. Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection. PLoS One 2009, 4(12):e8431.
40. Martel C.J., Aasted B. Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. Vet Immunol Immunopathol 2009, 132(December (2-4)):109-115.
41. Nishino M., Mizuno D., Kimoto T., Shinahara W., Fukuta A., Takei T., et al. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine 2009, 27(September (41)):5620-5627.